132 related articles for article (PubMed ID: 28659208)
1. [Intoxication with new psychoactive substances: drug unknown, but complications are still treatable].
Boersma MN; Nugteren-van Lonkhuyzen JJ; van Maarseveen EM; Kaasjager HAH; van Riel AJHP; Dekker D
Ned Tijdschr Geneeskd; 2017; 161():D1368. PubMed ID: 28659208
[TBL] [Abstract][Full Text] [Related]
2. The rise of new psychoactive substance use in Australia.
Burns L; Roxburgh A; Matthews A; Bruno R; Lenton S; Van Buskirk J
Drug Test Anal; 2014; 6(7-8):846-9. PubMed ID: 24599890
[TBL] [Abstract][Full Text] [Related]
3. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe.
Tang MH; Ching CK; Tsui MS; Chu FK; Mak TW
Clin Toxicol (Phila); 2014 Jun; 52(5):561-5. PubMed ID: 24779864
[TBL] [Abstract][Full Text] [Related]
4. I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances.
Matthews A; Sutherland R; Peacock A; Van Buskirk J; Whittaker E; Burns L; Bruno R
Int J Drug Policy; 2017 Feb; 40():44-49. PubMed ID: 27939599
[TBL] [Abstract][Full Text] [Related]
5. Phantom menace: novel psychoactive substances and the UK Armed Forces.
Hunter AH; Ayres T; Moreland N; Cox A
J R Army Med Corps; 2018 Nov; 164(6):450-457. PubMed ID: 29934414
[TBL] [Abstract][Full Text] [Related]
6. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).
Rickli A; Luethi D; Reinisch J; Buchy D; Hoener MC; Liechti ME
Neuropharmacology; 2015 Dec; 99():546-53. PubMed ID: 26318099
[TBL] [Abstract][Full Text] [Related]
7. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
[TBL] [Abstract][Full Text] [Related]
8. Next generation of novel psychoactive substances on the horizon - A complex problem to face.
Zawilska JB; Andrzejczak D
Drug Alcohol Depend; 2015 Dec; 157():1-17. PubMed ID: 26482089
[TBL] [Abstract][Full Text] [Related]
9. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
Palamar JJ; Martins SS; Su MK; Ompad DC
Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
[TBL] [Abstract][Full Text] [Related]
10. Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.
Palamar JJ; Acosta P; Sherman S; Ompad DC; Cleland CM
Am J Drug Alcohol Abuse; 2016 Nov; 42(6):624-632. PubMed ID: 27315522
[TBL] [Abstract][Full Text] [Related]
11. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.
Heikman P; Sundström M; Pelander A; Ojanperä I
Hum Psychopharmacol; 2016 Jan; 31(1):44-52. PubMed ID: 26763789
[TBL] [Abstract][Full Text] [Related]
12. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.
Schifano F; Papanti GD; Orsolini L; Corkery JM
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):943-54. PubMed ID: 26985969
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA).
Zwartsen A; Hondebrink L; Westerink RH
Neurotoxicology; 2018 May; 66():87-97. PubMed ID: 29572046
[TBL] [Abstract][Full Text] [Related]
14. New psychoactive substances: Purchasing and supply patterns in Australia.
Sutherland R; Bruno R; Peacock A; Dietze P; Breen C; Burns L; Barratt MJ
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28517235
[TBL] [Abstract][Full Text] [Related]
15. An overview of emerging and new psychoactive substances in the United Kingdom.
Beharry S; Gibbons S
Forensic Sci Int; 2016 Oct; 267():25-34. PubMed ID: 27552699
[TBL] [Abstract][Full Text] [Related]
16. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations.
Soussan C; Kjellgren A
Int J Drug Policy; 2016 Jun; 32():77-84. PubMed ID: 27184218
[TBL] [Abstract][Full Text] [Related]
17. Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach.
Caspar AT; Meyer MR; Maurer HH
Toxicol Lett; 2018 Mar; 285():1-8. PubMed ID: 29277574
[TBL] [Abstract][Full Text] [Related]
18. Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project.
Beck O; Franzén L; Bäckberg M; Signell P; Helander A
Clin Toxicol (Phila); 2016 Aug; 54(7):568-75. PubMed ID: 27412885
[TBL] [Abstract][Full Text] [Related]
19. The emergence of new psychoactive substance (NPS) benzodiazepines: A review.
Manchester KR; Lomas EC; Waters L; Dempsey FC; Maskell PD
Drug Test Anal; 2018 Jan; 10(1):37-53. PubMed ID: 28471096
[TBL] [Abstract][Full Text] [Related]
20. Assessing self-reported use of new psychoactive substances: The impact of gate questions.
Palamar JJ; Acosta P; Calderón FF; Sherman S; Cleland CM
Am J Drug Alcohol Abuse; 2017 Sep; 43(5):609-617. PubMed ID: 28485987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
